Neuren Pharmaceuticals Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume57,935 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive NEU News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.11 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Neuren Pharmaceuticals (ASX:NEU) Frequently Asked Questions

What stocks does MarketBeat like better than Neuren Pharmaceuticals?

Wall Street analysts have given Neuren Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neuren Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Neuren Pharmaceuticals' next earnings date?

Neuren Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 23rd 2021.
View our earnings forecast for Neuren Pharmaceuticals

How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Limited (ASX:NEU) released its earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share for the quarter.
View Neuren Pharmaceuticals' earnings history

Who are Neuren Pharmaceuticals' key executives?

Neuren Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA, CEO & MD
  • Ms. Lauren Frazer C.A., CFO & Company Sec.
  • Mr. Lawrence Glass, Chief Science Officer

Who are some of Neuren Pharmaceuticals' key competitors?

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Evolve Education Group (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Bingo Industries (BIN), Afterpay (APT) and Alkane Resources (ALK).

What is Neuren Pharmaceuticals' stock symbol?

Neuren Pharmaceuticals trades on the ASX under the ticker symbol "NEU."

How much money does Neuren Pharmaceuticals make?

Neuren Pharmaceuticals has a market capitalization of $0.00 and generates $717,000.00 in revenue each year.

How many employees does Neuren Pharmaceuticals have?

Neuren Pharmaceuticals employs 8 workers across the globe.

What is Neuren Pharmaceuticals' official website?

The official website for Neuren Pharmaceuticals is

How can I contact Neuren Pharmaceuticals?

The company can be reached via phone at 61 3 9092 0480.

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.